Drugs / mRNA Seasonal Flu vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07851246 | Oct 2026 → Jul 2027 expected | influenza | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT07805707 | Sep 2026 → Jun 2028 expected | influenza | GlaxoSmithKline | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-09-01 | GlaxoSmithKline | Results GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data gsk.com ↗
GSK’s vaccine candidate showed higher immune responses against all influenza strains tested compared to licensed standard dose and high dose inactivated flu vaccines in younger and older adults respectively, and was generally well tolerated. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-09-01 | GlaxoSmithKline | GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data gsk.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA Seasonal Flu vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07805707 ↗ |
| Known as | mRNA Flu vaccine | “One dose of the mRNA Flu vaccine received intramuscularly.” NCT07851246 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA Seasonal Flu vaccine” NCT07805707 ↗ |
| Route | Intramuscular | “received intramuscularly” NCT07851246 ↗ |